InflaRx N.V. develops anti-inflammatory therapeutics that target the complement system through proprietary anti-C5a and anti-C5aR technologies. Its lead program, izicopan, is an orally administered small-molecule inhibitor of C5a-induced signaling via the C5a receptor, and vilobelimab is an intravenously delivered anti-C5a monoclonal antibody that selectively binds free C5a.
Company news commonly covers izicopan clinical-development strategy, preclinical pharmacology data, complement-mediated inflammatory disease programs, financial results, ordinary-share financings, Nasdaq listing compliance, annual meeting matters and investor communications. Updates also address the company’s operating group, which includes wholly owned subsidiaries in Germany and the United States.
InflaRx (Nasdaq: IFRX) plans to begin two Phase 2 izicopan trials in ANCA-associated vasculitis (AAV) in 2027, with first data anticipated in 2028. The randomized study will test two doses against placebo, alongside standard care, in patients with kidney involvement; site initiation is expected in early 2027. An open-label study will explore replacing glucocorticoids, a type of corticosteroid, during treatment to induce remission.
Initial data from an investigator-initiated atypical hemolytic uremic syndrome study are expected in the second half of 2027. An IgA nephropathy pilot is planned for 2027, with early data expected in 2028. InflaRx estimates izicopan's peak AAV sales potential at $1.5–2.0 billion. Cash, cash equivalents and marketable securities totaled €153.3 million on September 30, 2026; the company expects funding to support operations and clinical development through 2029.
InflaRx (Nasdaq: IFRX) will report third-quarter 2026 financial and operating results before the market opens on November 3, 2026. Results will be submitted via Form 6-K to the SEC. A virtual Capital Markets Event that day, from 8:00 AM to approximately 9:00 AM EST, will include a quarterly results update and discussion of its development strategy and anticipated clinical program for ANCA-associated vasculitis.
InflaRx will hold a fireside chat at the Guggenheim Securities Healthcare Innovation Conference in Boston on November 10 at 9:30 AM EST, alongside one-on-one investor meetings. It will also hold investor meetings at the Jefferies Global Healthcare Conference in London on November 16 and 17.
InflaRx (IFRX) presented new preclinical izicopan results showing reduced kidney injury in two hamster models at Kidney Week 2026. In an acute kidney injury model, treatment reduced creatinine and blood urea nitrogen, both measures of kidney function, versus vehicle controls (p < 0.001 for both). In a progressive kidney injury model, treatment reduced blood urea nitrogen and improved tissue injury scores, but the trend toward reduced fibrosis was not statistically significant.
Structural modeling suggested a molecular basis for low potential to inhibit drug-metabolizing enzymes over time. InflaRx plans to develop izicopan for ANCA-associated vasculitis and additional kidney diseases.
InflaRx (IFRX) will present pre-clinical izicopan data in a late-breaking poster session at Kidney Week on October 22, 2026. The poster concerns izicopan’s therapeutic potential in kidney disease models. The session runs from 10:00 AM to 12:00 PM during the American Society of Nephrology’s meeting in Denver, Colorado, October 21–25.
Izicopan is an oral inhibitor of C5aR, a receptor involved in inflammation. InflaRx plans to develop it for ANCA-associated vasculitis and additional renal indications.
InflaRx (Nasdaq: IFRX) appointed Gabriela Alperovich as Senior Vice President and Global Head of Clinical Development, effective October 1, 2026.
Alperovich is a physician-scientist and nephrologist with more than two decades of pharmaceutical industry experience across clinical development and medical affairs. She joins from CSL Vifor, where she most recently served as Executive Director, Global Clinical Lead for Cardiovascular and Renal, overseeing development programs and a global team of physicians and clinical scientists.
Her previous leadership roles include positions at AbbVie and Bristol-Myers Squibb. She has led Phase 2/3 registrational programs, intended to support regulatory approval, across renal indications with successful submissions and approvals. She is board certified in Internal Medicine and Nephrology and holds a PhD in kidney transplant from the University of Barcelona.
InflaRx (IFRX) will host a virtual Capital Markets Event on November 3, 2026, from 8:00–9:00 AM EST (2:00–3:00 PM CET).
The event timing was adjusted to align with scheduling needs and clinical development planning in ANCA-associated vasculitis (AAV). Presentations will cover the AAV treatment landscape, unmet medical need, and how InflaRx’s oral C5a receptor inhibitor izicopan might improve upon current standard of care, along with an overview of the anticipated clinical program in AAV. Featured speakers include AAV expert Dr. Peter A. Merkel and complement biology expert Prof. Dr. Jörg Köhl, alongside InflaRx management, followed by a question-and-answer session.
InflaRx (Nasdaq: IFRX) announced its participation in two investor conferences in September 2026 in New York.
At the Cantor Global Healthcare Conference 2026, the company will join a fireside chat on September 9, 2026 at 3:20 PM ET and hold one-on-one investor meetings the same day. A live and replay link will be made available online.
At the H.C. Wainwright 28th Annual Global Investment Conference, InflaRx will present on September 14, 2026 at 10:00 AM ET and also conduct one-on-one meetings, with registration and replay access provided via an online link.
InflaRx (Nasdaq: IFRX) reported second quarter 2026 results and a strategic refocus on izicopan, its next-generation oral C5aR inhibitor, for ANCA-associated vasculitis (AAV) and select renal diseases including aHUS, IgAN and C3G. Phase 2 planning in AAV and open-label renal proof-of-concept studies are underway, with initial renal data targeted for 2027.
InflaRx plans a PK bridging study with izicopan in China in late 2026 to accelerate additional inflammation and immunology indications and intends to engage EMA on vilobelimab and izicopan in AAV following CHMP’s recommendation to revoke Tavneos’ EU marketing authorization. In May, the company completed a $150 million underwritten offering (75 million shares at $2.00), generating €119.3 million net, strengthening total funds to €158.4 million at June 30, 2026, which management expects will fund operations and development through 2029.
For the six months ended June 30, 2026, InflaRx recorded a net loss of €16.2 million (€0.17 per share), improved from €22.7 million (€0.35 per share) a year earlier, driven by lower R&D, sales and marketing, and G&A expenses.
InflaRx (Nasdaq: IFRX) announced it will report its second quarter 2026 financial and operating results on August 6, 2026, before the U.S. market opens. The company does not plan to hold a conference call in connection with this release.
InflaRx is a biopharmaceutical company focused on anti-inflammatory therapeutics targeting the complement factor C5a and its receptor C5aR. Its lead oral small-molecule program, izicopan, is being developed for ANCA-associated vasculitis and additional renal diseases, while vilobelimab, an intravenously delivered monoclonal antibody, has shown clinical activity and tolerability in multiple studies.
InflaRx (Nasdaq: IFRX) is assessing a broadened ANCA-associated vasculitis (AAV) strategy in Europe after the EMA committee recommended revoking Tavneos’ EU authorization. The company plans EMA discussions on vilobelimab and oral izicopan, continues Phase 2 izicopan AAV planning, highlights Phase 2 vilobelimab AAV data, partner-led BDB-001 Phase 3 in China, and ongoing EU and US authorizations for GOHIBIC (vilobelimab) in COVID-19 ARDS.